A Phase 3 interventional study of Keppra XR and Keppra XR in Epilepsy, sponsored by UCB Pharma. Completed at 46 sites in 4 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-09-05.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.
Among the 60 studies testing levetiracetam in Epilepsy, this one is the 14th largest by enrollment, is one of 7 that started in 2007, is one of 28 in phase 3, and was the 19th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Waad Alkathiri · Sites in Saudi Arabia
Ages 18+
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
National Taiwan University Hospital
Ages 20+
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 28 · Phase 4 13
First in 1998; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 228 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 60 interventional studies. Of the 55 that completed or were terminated, 31 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 40th largest by enrollment of the 116 interventional ones that give a count, is one of 9 that started in 2007, is one of 74 in phase 3, and was the 28th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing levetiracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1000 mg/day once daily for 18 weeks (administered as two levetiracetam XR tablets and two placebo tablets once daily)
Drug: Keppra XR
2000 mg/day once daily for 18 weeks (administered as four levetiracetam XR tablets once daily)
Drug: Keppra XR
The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase
Cumulative exit rate at day 112, based on the duration between start date of previous AED tapering to the earliest date exit criterion was met; calculated using Kaplan Meier Methods. Subjects prematurely discontinued for reasons unrelated to exit criteria were censored as of last dose of study drug. Subjects who completed without meeting exit criteria were censored at Day 112. Exit criteria include increase in seizure frequency, severity, duration, status epilepticus, or new generalized seizure. Upper 95% 2-sided confidence limit for exit rate is compared to the historical control rate: 0.678.
Time frame: 112 days
The Cumulative Rate of Exit Events, Which Include Discontinuation Due to Exit Criteria, Withdrawal Due to Adverse Events (AE) and Withdrawal Due to Lack of Efficacy, at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase
The cumulative exit event rate at Day 112 was calculated using Kaplan Meier methods. The exit event rate estimate was based on the duration between the start date of previous AED tapering to the earliest date an exit event occured. Subjects who prematurely discontinued for reasons unrelated to exit criteria, adverse event, or lack of efficacy were censored as of the last dose of study medication. Subjects who completed the study without having an exit event were censored as of Day 112.
Time frame: 112 days
The Cumulative Rate of Exit Events Due to Any Reasons at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase
The cumulative exit event rate at Day 112 was calculated using Kaplan Meier methods. The exit event rate estimate was based on the duration between the start date of previous AED tapering to the earliest date an exit event occured. Subjects who completed the study without having an exit event were censored as of Day 112.
Time frame: 112 days
The Cumulative Exit Rate at 112 Days for the Keppra XR 1000 mg Group After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase
Keppra XR 1000 mg arm was not intended for inferential analysis (planned 3 to 1 randomization, Keppra XR 2000 mg: 1000 mg). The Exit Rate was based on the duration between the start date of previous AED tapering to the earliest date an exit crterion was met. Subjects who prematurely discontinued for reasons unrelated to exit criteria were censored as of the last dose of study medication. Subjects who completed the study without meeting an exit criterion were censored as of Day 112.
Time frame: 112 days
The Efficacy (EFF) population is defined as all subjects in the Intent to Treat (ITT) population who enter into the Previous Antiepileptic (AED) Discontinuation (D/C) Phase. The Per Protocol (PP) population consists of all subjects in the EFF population who have no important protocol deviations related to efficacy.
| Milestone | Keppra XR 1000 mg/Day | Keppra XR 2000 mg/Day |
|---|---|---|
| Started | 57 | 171 |
| Completed | 50 | 141 |
| Not completed | 7 | 30 |
| Withdrew: Adverse event | 3 | 7 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Protocol violation | 1 | 14 |
| Withdrew: Withdrawal of consent | 1 | 5 |
| Withdrew: Other: error determining exit criteria | 1 | 0 |
| Withdrew: Other: patient non-compliant | 0 | 1 |
| Withdrew: Other: no contact for extended period | 0 | 1 |
Cumulative exit rate at day 112, based on the duration between start date of previous AED tapering to the earliest date exit criterion was met; calculated using Kaplan Meier Methods. Subjects prematurely discontinued for reasons unrelated to exit criteria were censored as of last dose of study drug. Subjects who completed without meeting exit criteria were censored at Day 112. Exit criteria include increase in seizure frequency, severity, duration, status epilepticus, or new generalized seizure. Upper 95% 2-sided confidence limit for exit rate is compared to the historical control rate: 0.678.
| proportion of subjects | Keppra XR 1000 mg/Day | Keppra XR 2000 mg/Day |
|---|---|---|
| The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase | — | 0.375 (0.297 to 0.453) |
The cumulative exit event rate at Day 112 was calculated using Kaplan Meier methods. The exit event rate estimate was based on the duration between the start date of previous AED tapering to the earliest date an exit event occured. Subjects who prematurely discontinued for reasons unrelated to exit criteria, adverse event, or lack of efficacy were censored as of the last dose of study medication. Subjects who completed the study without having an exit event were censored as of Day 112.
| proportion of subjects | Keppra XR 1000 mg/Day | Keppra XR 2000 mg/Day |
|---|---|---|
| The Cumulative Rate of Exit Events, Which Include Discontinuation Due to Exit Criteria, Withdrawal Due to Adverse Events (AE) and Withdrawal Due to Lack of Efficacy, at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase | — | 0.385 (0.307 to 0.463) |
The cumulative exit event rate at Day 112 was calculated using Kaplan Meier methods. The exit event rate estimate was based on the duration between the start date of previous AED tapering to the earliest date an exit event occured. Subjects who completed the study without having an exit event were censored as of Day 112.
| proportion of subjects | Keppra XR 1000 mg/Day | Keppra XR 2000 mg/Day |
|---|---|---|
| The Cumulative Rate of Exit Events Due to Any Reasons at 112 Days After the Beginning of Previous Antiepileptic Drug (AED) Tapering Phase | — | 0.475 (0.397 to 0.553) |
Keppra XR 1000 mg arm was not intended for inferential analysis (planned 3 to 1 randomization, Keppra XR 2000 mg: 1000 mg). The Exit Rate was based on the duration between the start date of previous AED tapering to the earliest date an exit crterion was met. Subjects who prematurely discontinued for reasons unrelated to exit criteria were censored as of the last dose of study medication. Subjects who completed the study without meeting an exit criterion were censored as of Day 112.
| proportion of subjects | Keppra XR 1000 mg/Day | Keppra XR 2000 mg/Day |
|---|---|---|
| The Cumulative Exit Rate at 112 Days for the Keppra XR 1000 mg Group After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase | 0.334 (0.204 to 0.465) | — |
Collected over Up to 29 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Keppra XR 1000 mg/Day | — | 2/57 (3.5%) | 33/57 (57.9%) |
| Keppra XR 2000 mg/Day | — | 12/171 (7%) | 87/171 (50.9%) |
| Event | Keppra XR 1000 mg/Day | Keppra XR 2000 mg/Day |
|---|---|---|
| convulsionNervous system disorders | 1/57 | 4/171 |
| acute psychosisPsychiatric disorders | 1/57 | 0/171 |
| haemorrhoidal haemorrhageGastrointestinal disorders | 0/57 | 1/171 |
| pancreatitis acuteGastrointestinal disorders | 0/57 | 1/171 |
| pulmonary tuberculosisInfections and infestations | 0/57 | 1/171 |
| pyelonephritisInfections and infestations | 0/57 | 1/171 |
| ankle fractureInjury, poisoning and procedural complications | 0/57 | 1/171 |
| back painMusculoskeletal and connective tissue disorders | 0/57 | 1/171 |
| intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/57 | 1/171 |
| lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/57 | 1/171 |
| Event | Keppra XR 1000 mg/Day | Keppra XR 2000 mg/Day |
|---|---|---|
| headacheNervous system disorders | 13/57 | 32/171 |
| somnolenceNervous system disorders | 12/57 | 38/171 |
| convulsionNervous system disorders | 9/57 | 20/171 |
| dizzinessNervous system disorders | 3/57 | 15/171 |
| irritablilityGeneral disorders | 3/57 | 12/171 |
| vertigoEar and labyrinth disorders | 3/57 | 7/171 |
| abdominal painGastrointestinal disorders | 3/57 | 6/171 |
| nasopharyngitisInfections and infestations | 3/57 | 7/171 |
| Age, Categorical(Participants) | Keppra XR 1000 mg/Day | Keppra XR 2000 mg/Day | Total |
|---|---|---|---|
| <=18 years | 11 | 31 | 42 |
| Between 18 and 65 years | 43 | 140 | 183 |
| >=65 years | 3 | 0 | 3 |
| Age, Continuous(years) | Keppra XR 1000 mg/Day | Keppra XR 2000 mg/Day | Total |
|---|---|---|---|
| Mean | 33.48 ± 16.32 | 34.31 ± 13.69 | 34.11 ± 14.36 |
| Sex: Female, Male(Participants) | Keppra XR 1000 mg/Day | Keppra XR 2000 mg/Day | Total |
|---|---|---|---|
| Female | 33 | 99 | 132 |
| Male | 24 | 72 | 96 |
| Region of Enrollment(participants) | Keppra XR 1000 mg/Day | Keppra XR 2000 mg/Day | Total |
|---|---|---|---|
| United States | 8 | 29 | 37 |
| Mexico | 17 | 43 | 60 |
| Poland | 16 | 51 | 67 |
| Russian Federation | 16 | 48 | 64 |
The record gives a start of Aug 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam